104 related articles for article (PubMed ID: 26637407)
21. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
22. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
Horazeck C; Huh AS; Huh BK
Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
[TBL] [Abstract][Full Text] [Related]
23. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
24. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
26. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
[TBL] [Abstract][Full Text] [Related]
28. In reply.
Auchus RJ; Yu MK; Nguyen S; Mundle SD
Oncologist; 2015 May; 20(5):e14. PubMed ID: 25888269
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone--what is wrong with the adrenal glands?
Schmid S; Fornaro J; Rothermundt C; Omlin A; Brändle M; Rupp NJ; Gillessen S
Clin Genitourin Cancer; 2014 Aug; 12(4):e133-7. PubMed ID: 24583161
[No Abstract] [Full Text] [Related]
30. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
[TBL] [Abstract][Full Text] [Related]
31. [Rhabdomyolysis following therapeutic doses of oral and injectable morphine].
Molia A; Novella JL; Frances C; Jochum C; Blanchard F; Trenque T
Therapie; 2002; 57(6):595-7. PubMed ID: 12666270
[No Abstract] [Full Text] [Related]
32. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
Anticancer Drugs; 2014 Apr; 25(4):472-7. PubMed ID: 24394473
[TBL] [Abstract][Full Text] [Related]
33. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
34. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
[TBL] [Abstract][Full Text] [Related]
35. [Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
Rexer H
Urologe A; 2014 Nov; 53(11):1665-7. PubMed ID: 25297491
[No Abstract] [Full Text] [Related]
36. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
37. Abiraterone-Associated Fulminant Liver Failure.
Singh P; Sinha A; Lama Tamang TG; Chandra AB; Huang YJ
Am J Ther; 2018; 25(4):e505-e506. PubMed ID: 28452846
[No Abstract] [Full Text] [Related]
38. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O; De Giorgi U; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Macrini S; Messina C; Giordano M; Alesini D; Zustovich F; Fraccon AP; Vicario G; Conteduca V; Maines F; Galligioni E
BJU Int; 2015 May; 115(5):764-71. PubMed ID: 24988879
[TBL] [Abstract][Full Text] [Related]
39. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
[TBL] [Abstract][Full Text] [Related]
40. Corticosteroids and prostate cancer: friend or foe?
Geynisman DM; Szmulewitz RZ; Plimack ER
Eur Urol; 2015 May; 67(5):874-5. PubMed ID: 25151018
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
